Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 12—December 2018

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1

Martin HoeniglComments to Author , Sonia Jain, David Moore, Deborah Collins, Xiaoying Sun, Peter L. Anderson, Katya Corado, Jill S. Blumenthal, Eric S. Daar, Joel Milam, Michael P. Dubé, Sheldon Morris, and for the California Collaborative Treatment Group 595 Team
Author affiliations: Medical University of Graz, Graz, Austria (M. Hoenigl); University of California, San Diego, California, USA (M. Hoenigl, S. Jain, D. Moore, X. Sun, J.S. Blumenthal, S. Morris); Department of Health and Human Services, Long Beach, California, USA (D. Collins); University of Anschutz Medical Campus, Aurora, Colorado, USA (P.L. Anderson); Harbor UCLA Medical Center, Torrance, California, USA (K. Corado, E.S. Daar); University of Southern California Keck School of Medicine, Los Angeles, California, USA (J. Milam, M.P. Dubé)

Main Article

Table 4

Cox regression models used for assessing substance use and early study termination and incident STIs among MSM and transgender women, California, USA*

Model HR (95% CI) p value
Model 1
Intervention arm (receiving individualized texting for adherence to daily TDF/FTC) 1.377 (0.862–2.200) 0.180
Baseline some substance use (any) 0.743 (0.426–1.293) 0.293
Baseline frequent substance use (any) 0.541 (0.304–0.961) 0.036
Model 2
Intervention arm 0.924 (0.671–1.272) 0.626
Age 0.973 (0.955–0.992) 0.005
Baseline some stimulant use 2.690 (1.727–4.190) <0.001
Baseline frequent stimulant use 2.604 (1.665–4.072) <0.001
Positive STI test result at baseline 1.450 (1.031–2.039) 0.033

*Model 1 assessed the effect of baseline substance use on early study termination. Model 2 assessed the association of stimulant use and incident STIs during the study. FTC, emtricitibine; HR, hazard ratio; MSM, men who have sex with men; STI, sexually transmitted infection; TDF, tenofovir disoproxil fumarate.

Main Article

1Original data from this study were presented in part at the 2017 Conference on Retroviruses and Opportunistic Infections, February 13–16, 2017, Seattle, Washington, USA; and at the 12th International Conference on HIV Treatment and Prevention Adherence, June 4–6, 2017, Miami, Florida, USA.

Page created: November 14, 2018
Page updated: November 14, 2018
Page reviewed: November 14, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.